Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940970 | 0.84 | DGAT1 (0.37) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL31710459 | 0.84 | DGAT1 (0.35) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL29514152 | 0.84 | DGAT1 (0.40) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL13521539 | 0.84 | DGAT1 (0.35) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL352030 | 0.84 | FGFR1 (0.35) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL29854726 | 0.84 | FGFR1 (0.35) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL101528 | 0.84 | DGAT1 (0.40) | DGAT1NPC1MAPTDUTEGFR | |
| SCHEMBL99396 | 0.83 | DGAT1 (0.33) | DGAT1NPC1MAPT | |
| SCHEMBL21632481 | 0.82 | DGAT1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL21632543 | 0.82 | MAPT (0.35) | DGAT1NPC1MAPTEGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| CN-117425660-A | Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023222005-A1 | AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-11-23 | — | — | WO | disclosed |
| CN-113620956-B | Transforming growth factor receptor antagonist, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4182323-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-05-02 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| CN-1198804-C | Amide compounds and use thereof | MITSUBISHI SEIYAKU CO LTD (JP) | 2005-04-27 | — | — | CN | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| CN-1418194-A | Amide compounds and use thereof | MITSUBISHI SEIYAKU CO LTD (JP) | 2003-05-14 | — | — | CN | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | DGAT1 2691/4885NPC1 1207/4885MAPT 1859/4885 |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | DGAT1 4366/4885NPC1 1523/4885MAPT 3319/4885 |
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | DGAT1 3919/4885NPC1 2707/4885MAPT 738/4885 |
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | DGAT1 2833/4885NPC1 2927/4885MAPT 3509/4885 |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | JAK2, JAK1, JAK3 | DGAT1 2833/4885NPC1 2927/4885MAPT 3509/4885 |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | DGAT1 4181/4885NPC1 3691/4885MAPT 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.